Literature DB >> 17431188

Dietary fat-induced alterations in atherosclerosis are abolished by ACAT2-deficiency in ApoB100 only, LDLr-/- mice.

Thomas A Bell1, Kathryn Kelley, Martha D Wilson, Janet K Sawyer, Lawrence L Rudel.   

Abstract

OBJECTIVES: The enzyme acyl-coenzymeA (CoA):cholesterol O-acyltransferase 2 (ACAT2) in the liver synthesizes cholesteryl esters (CE) from cholesterol and fatty acyl-CoA, which get incorporated into apoB-containing lipoproteins that are secreted into the bloodstream. Dietary fatty acid composition influences the amount and fatty acid composition of CE within apoB-containing lipoproteins. We hypothesized that when ACAT2 activity is removed by gene deletion, hepatic CE synthesis and secretion would be minimal and, as a result, dietary fat-related differences in atherosclerosis would be eliminated. METHODS AND
RESULTS: Groups of female apoB100 only, LDLr-/- mice with and without ACAT2 were fed diets enriched in either omega-3 or omega-6 polyunsaturated fat, saturated fat, and cis or trans monounsaturated fat. After 20 weeks on diet, mice fed diets enriched in monounsaturated or saturated fat exhibited significantly higher amounts of plasma cholesterol, larger LDL particles enriched in monounsaturated CE, and more atherosclerosis than mice fed polyunsaturated fat. The dietary fat-induced shifts in plasma cholesterol, LDL size, LDL CE composition, and atherosclerosis were not observed in ACAT2-/- mice. Regardless of the diet fed, the ACAT2-/- mice were protected from atherosclerosis.
CONCLUSIONS: The results indicate that in apoB100 only, LDLr-/- mice, ACAT2 plays an essential role in facilitating dietary fat type-specific atherosclerosis through its various effects on plasma lipoprotein concentration and composition.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17431188     DOI: 10.1161/ATVBAHA.107.142802

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  24 in total

Review 1.  Dietary monounsaturated fatty acids appear not to provide cardioprotection.

Authors:  Chiara Degirolamo; Lawrence L Rudel
Journal:  Curr Atheroscler Rep       Date:  2010-11       Impact factor: 5.113

2.  Macrophage 12/15 lipoxygenase expression increases plasma and hepatic lipid levels and exacerbates atherosclerosis.

Authors:  Shunxing Rong; Qiang Cao; Mingxia Liu; Jeongmin Seo; Lin Jia; Elena Boudyguina; Abraham K Gebre; Perry L Colvin; Thomas L Smith; Robert C Murphy; Nilamadhab Mishra; John S Parks
Journal:  J Lipid Res       Date:  2012-01-25       Impact factor: 5.922

3.  Epigenetic control of lipid metabolism: implications for lifespan and healthspan.

Authors:  Gabriele G Schiattarella; Joseph A Hill
Journal:  Cardiovasc Res       Date:  2018-05-01       Impact factor: 10.787

4.  LDL particle core enrichment in cholesteryl oleate increases proteoglycan binding and promotes atherosclerosis.

Authors:  John T Melchior; Janet K Sawyer; Kathryn L Kelley; Ramesh Shah; Martha D Wilson; Roy R Hantgan; Lawrence L Rudel
Journal:  J Lipid Res       Date:  2013-06-26       Impact factor: 5.922

5.  Botanical oils enriched in n-6 and n-3 FADS2 products are equally effective in preventing atherosclerosis and fatty liver.

Authors:  Swapnil V Shewale; Elena Boudyguina; Xuewei Zhu; Lulu Shen; Patrick M Hutchins; Robert M Barkley; Robert C Murphy; John S Parks
Journal:  J Lipid Res       Date:  2015-04-28       Impact factor: 5.922

6.  Sterol O-Acyltransferase 2-Driven Cholesterol Esterification Opposes Liver X Receptor-Stimulated Fecal Neutral Sterol Loss.

Authors:  Manya Warrier; Jun Zhang; Kanwardeep Bura; Kathryn Kelley; Martha D Wilson; Lawrence L Rudel; J Mark Brown
Journal:  Lipids       Date:  2016-01-04       Impact factor: 1.880

7.  Targeted depletion of hepatic ACAT2-driven cholesterol esterification reveals a non-biliary route for fecal neutral sterol loss.

Authors:  J Mark Brown; Thomas A Bell; Heather M Alger; Janet K Sawyer; Thomas L Smith; Kathryn Kelley; Ramesh Shah; Martha D Wilson; Matthew A Davis; Richard G Lee; Mark J Graham; Rosanne M Crooke; Lawrence L Rudel
Journal:  J Biol Chem       Date:  2008-02-14       Impact factor: 5.157

8.  Targeted Knockdown of Hepatic SOAT2 With Antisense Oligonucleotides Stabilizes Atherosclerotic Plaque in ApoB100-only LDLr-/- Mice.

Authors:  John T Melchior; John D Olson; Kathryn L Kelley; Martha D Wilson; Janet K Sawyer; Kerry M Link; Lawrence L Rudel
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-07-30       Impact factor: 8.311

9.  New pyripyropene A derivatives, highly SOAT2-selective inhibitors, improve hypercholesterolemia and atherosclerosis in atherogenic mouse models.

Authors:  Taichi Ohshiro; Masaki Ohtawa; Tohru Nagamitsu; Daisuke Matsuda; Hiroaki Yagyu; Matthew A Davis; Lawrence L Rudel; Shun Ishibashi; Hiroshi Tomoda
Journal:  J Pharmacol Exp Ther       Date:  2015-09-03       Impact factor: 4.030

10.  Histone deacetylase inhibitors: a new mode for inhibition of cholesterol metabolism.

Authors:  Sridar V Chittur; Niquiche Sangster-Guity; Paulette J McCormick
Journal:  BMC Genomics       Date:  2008-10-29       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.